- Home
- TNFA
TNFA
TNF PHARMACEUTICALS INC EFFEC
as 03-28-2025 4:00pm EST
Stocks
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BALTIMORE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 272.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.33 - $3.50 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest TNF PHARMACEUTICALS INC EFFEC News
TNFA Breaking Stock News: Dive into TNFA Ticker-Specific Updates for Smart Investing
TipRanks
13 days ago
TNF Pharmaceuticals presents isomyosamine data
Business Wire
14 days ago
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
Business Wire
a month ago
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
Business Wire
a month ago
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
Business Wire
2 months ago
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
Business Wire
3 months ago
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
Business Wire
3 months ago
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
Business Wire
4 months ago
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
Compare TNFA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNFA TNF PHARMACEUTICALS INC EFFEC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.